Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
Lawler P, Manvelian G, Coppi A, Damask A, Cantor M, Ferreira M, Paulding C, Banerjee N, Li D, Jorgensen S, Attre R, Carey D, Krebs K, Milani L, Hveem K, Damås J, Solligård E, Stender S, Tybjærg-Hansen A, Nordestgaard B, Hernandez-Beeftink T, Rogne T, Flores C, Villar J, Walley K, Liu V, Fohner A, Lotta L, Kyratsous C, Sleeman M, Scemama M, DelGizzi R, Pordy R, Horowitz J, Baras A, Martin G, Steg P, Schwartz G, Szarek M, Goodman S. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis. Critical Care Explorations 2023, 5: e0997. PMID: 37954898, PMCID: PMC10635596, DOI: 10.1097/cce.0000000000000997.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Convertase subtilisin/kexin type 9Subtilisin/kexin type 9Human cohort studiesODYSSEY OUTCOMESCohort studyType 9Isotype-matched controlExperimental murine modelSepsis ratePCSK9 inhibitionPCSK9 inhibitorsSepsis complicationsSepsis mortalitySepsis outcomeImproved survivalBacterial sepsisClinical outcomesBloodstream clearanceSepsis modelClinical trialsOdds ratioCardiovascular diseasePretreatment settingSepsis diagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply